欢迎来到CSNpharm!产品仅用于科研!

400-920-2911 sales@csnpharm.cn

0

C3 plays a central role in the activation of the complement system. Its processing by C3 convertase is the central reaction in both classical and alternative complement pathways. After activation C3b can bind covalently, via its reactive thioester, to cell surface carbohydrates or immune aggregates. Derived from proteolytic degradation of complement C3, C3a anaphylatoxin is a mediator of local inflammatory process. In chronic inflammation, acts as a chemoattractant for neutrophils (By similarity). It induces the contraction of smooth muscle, increases vascular permeability and causes histamine release from mast cells and basophilic leukocytes.

Complement C3

货号 产品名 CAS号 信息
CSN27744 2-((4R,7S,10S,13S,19S,22S,25S,28S,31S,34R)-10-((1H-Imidazol-5-yl)methyl)-19-((1H-indol-3-yl)methyl)-34-((2S,3S)-2-((R)-2-amino-3-(4-hydroxyphenyl)propanamido)-3-methylpentanamido)-4-(((2S,3S)-1-amino-3-methyl-1-oxopentan-2-yl)(methyl)carbamoyl)-25-(3-amino-3-oxopropyl)-7-(3-guanidinopropyl)-31-isopropyl-13,17-dimethyl-28-((1-methyl-1H-indol-3-yl)methyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decaazacyclopentatriacontan-22-yl)acetic acid compound acetic acid salt N/A AMY 101 is a peptidic central complement component C3 inhibitor with Kd value of 0.5nM. It is now in phase 2 study of Gingivitis, Periodontitis and SARS-CoV-2 acute respiratory disease.
<< PREV 1 NEXT >>
联系
我们